IN163129B - - Google Patents

Info

Publication number
IN163129B
IN163129B IN921/MAS/86A IN921MA1986A IN163129B IN 163129 B IN163129 B IN 163129B IN 921MA1986 A IN921MA1986 A IN 921MA1986A IN 163129 B IN163129 B IN 163129B
Authority
IN
India
Application number
IN921/MAS/86A
Other languages
English (en)
Inventor
James Edward Jeffery
Derek Whybrow
Original Assignee
Boots Co Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10589895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN163129(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boots Co Plc filed Critical Boots Co Plc
Publication of IN163129B publication Critical patent/IN163129B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN921/MAS/86A 1985-12-17 1986-11-28 IN163129B (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858531071A GB8531071D0 (en) 1985-12-17 1985-12-17 Therapeutic compound

Publications (1)

Publication Number Publication Date
IN163129B true IN163129B (OSRAM) 1988-08-13

Family

ID=10589895

Family Applications (1)

Application Number Title Priority Date Filing Date
IN921/MAS/86A IN163129B (OSRAM) 1985-12-17 1986-11-28

Country Status (34)

Country Link
US (2) US4929629A (OSRAM)
EP (1) EP0230742B1 (OSRAM)
JP (1) JPS62155240A (OSRAM)
KR (1) KR940008913B1 (OSRAM)
CN (1) CN1016245B (OSRAM)
AT (1) ATE56942T1 (OSRAM)
AU (1) AU601167B2 (OSRAM)
CA (1) CA1266278A (OSRAM)
CS (1) CS259545B2 (OSRAM)
DD (1) DD263050A5 (OSRAM)
DE (1) DE3674570D1 (OSRAM)
DK (1) DK170770B1 (OSRAM)
EG (1) EG17770A (OSRAM)
ES (1) ES2018163T4 (OSRAM)
FI (1) FI90413C (OSRAM)
GB (1) GB8531071D0 (OSRAM)
GE (1) GEP19970812B (OSRAM)
GR (1) GR3001069T3 (OSRAM)
HU (1) HU201901B (OSRAM)
IE (1) IE59429B1 (OSRAM)
IL (1) IL80934A (OSRAM)
IN (1) IN163129B (OSRAM)
LU (1) LU90865I2 (OSRAM)
MX (1) MX4684A (OSRAM)
NL (1) NL300065I1 (OSRAM)
NO (2) NO165540C (OSRAM)
NZ (1) NZ218578A (OSRAM)
PH (1) PH22481A (OSRAM)
PL (1) PL149519B1 (OSRAM)
PT (1) PT83958B (OSRAM)
SU (1) SU1443796A3 (OSRAM)
UA (1) UA7206A1 (OSRAM)
YU (1) YU46033B (OSRAM)
ZA (1) ZA869078B (OSRAM)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
WO1994000114A1 (en) * 1992-06-23 1994-01-06 Sepracor Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
WO1994000047A1 (en) * 1992-06-23 1994-01-06 Sepracor Inc. Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
DE4443891A1 (de) * 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9619961D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
AU2730800A (en) * 1999-01-20 2000-08-07 Abbott Laboratories Method to aid smoking cessation
BG65170B1 (bg) * 1999-03-17 2007-05-31 Knoll Gmbh Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
WO2000056309A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Method of treating sexual dysfunction
BR0009161A (pt) * 1999-03-19 2002-01-22 Knoll Gmbh Tratamento de certos cânceres associados a ganho de peso
AU3895300A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6365632B1 (en) 1999-03-19 2002-04-02 Knoll Pharmaceuticals Company Treatment of orthostatic hypotension
WO2000056308A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Prevention of cardiovascular disease
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US6376553B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Treatment of pain
HUP0200501A3 (en) * 1999-03-19 2004-03-29 Abbott Gmbh & Co Kg Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for treating sleep apnoea
US6441046B1 (en) 1999-03-19 2002-08-27 Abbott Gmbh & Co. Kg Control of metabolism
IL145238A0 (en) * 1999-03-19 2002-06-30 Knoll Gmbh Treatment of osteoarthritis
WO2000056321A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
US6403650B1 (en) 1999-03-19 2002-06-11 Knoll Pharmaceutical Company Treatment of pulmonary hypertension
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
PE20011065A1 (es) 2000-02-01 2001-11-21 Procter & Gamble Proceso para fabricar bisfosfonatos geminales
US6410520B2 (en) 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
US6232347B1 (en) 2000-03-17 2001-05-15 Knoll Pharmaceutical Company Treatment of osteoarthritis
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
WO2003077847A2 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
KR100536750B1 (ko) * 2002-10-05 2005-12-16 한미약품 주식회사 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
AU2003264968B2 (en) * 2002-10-05 2006-03-16 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
GB0310361D0 (en) * 2003-05-06 2003-06-11 Cipla Ltd Pharmaceutical compound
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
AU2005308575A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
WO2006073292A1 (en) 2005-01-06 2006-07-13 Cj Corporation Inorganic acid salts of sibutramine
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
KR100781882B1 (ko) * 2005-07-12 2007-12-05 주식회사유한양행 시부트라민을 함유하는 약제학적 조성물
WO2007015162A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
WO2007034910A1 (ja) * 2005-09-22 2007-03-29 Eisai R & D Management Co., Ltd. 過食症及び過食症に伴ううつ病の治療用医薬組成物
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
EP1989196B1 (en) * 2006-02-23 2013-02-13 Pfizer Limited Piperidinoylpyrrolidines as melanocortin type 4 receptor agonists
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
AU2007296074B2 (en) * 2006-09-15 2012-07-12 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
WO2008059335A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
US20080182851A1 (en) * 2006-11-20 2008-07-31 Glenmark Pharmaceuticals S.A. Acetylene derivatives as stearoyl coa desaturase inhibitors
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US20080221057A1 (en) * 2007-02-16 2008-09-11 Wyeth Secreted protein ccdc80 regulates adipocyte differentiation
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
EP2131835A1 (en) * 2007-04-09 2009-12-16 Scidose, Llc Combinations of statins and anti-obesity agent
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
AU2009278838B2 (en) * 2008-08-06 2013-07-25 Pfizer Limited Diazepine and diazocane compounds as MC4 agonists
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2395987A1 (en) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
PT2496583E (pt) 2009-11-02 2015-01-14 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
TR201802207T4 (tr) 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
EP2590969B1 (en) 2010-07-06 2014-10-15 AstraZeneca AB Therapeutic agents 976
SI3023102T1 (sl) 2010-11-04 2018-11-30 Albireo Ab IBAT inhibitorji za zdravljenje jetrnih bolezni
WO2012064267A1 (en) 2010-11-08 2012-05-18 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
CN110372522B (zh) * 2019-07-30 2020-10-02 南京工业大学 一种从含有戊二胺的固相中汽提回收戊二胺的方法
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1124485B (de) * 1960-02-12 1962-03-01 Hoechst Ag Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen
SE7600674L (sv) * 1975-02-05 1976-08-06 Rohm & Haas Fungicider
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
US4443449A (en) * 1981-04-06 1984-04-17 The Boots Company Limited Arylcyclobutylalkylamines and anti-depression composition and methods using same
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB2115409B (en) * 1982-02-24 1985-08-07 Zyma Sa Novel crystal modifications of (+)-catechin
DK101683A (da) * 1982-03-12 1983-09-13 Duphar Int Res Phenylpiperazinderivater og fremgangsmaade til fremstilling heraf
IE56000B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylalkylamine compounds
IE56001B1 (en) * 1982-09-30 1991-03-13 Boots Co Plc 1-arylcyclobutylmethylamine compounds
ZA836848B (en) * 1982-09-30 1984-05-30 Boots Co Plc Therapeutic agents
GB8501192D0 (en) * 1985-01-17 1985-02-20 Boots Co Plc Therapeutic agents
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity

Also Published As

Publication number Publication date
DK585786A (da) 1987-06-18
CS930586A2 (en) 1988-02-15
AU6644286A (en) 1987-06-18
DK170770B1 (da) 1996-01-15
KR940008913B1 (ko) 1994-09-28
DE3674570D1 (de) 1990-10-31
PL149519B1 (en) 1990-02-28
AU601167B2 (en) 1990-09-06
YU46033B (sh) 1992-12-21
FI90413B (fi) 1993-10-29
PT83958A (en) 1987-01-01
EP0230742B1 (en) 1990-09-26
ES2018163B3 (es) 1991-04-01
NZ218578A (en) 1989-04-26
CS259545B2 (en) 1988-10-14
PL263020A1 (en) 1988-05-12
GEP19970812B (en) 1997-02-10
PH22481A (en) 1988-09-12
CA1266278A (en) 1990-02-27
NO865093D0 (no) 1986-12-16
HU201901B (en) 1991-01-28
LU90865I2 (fr) 2002-02-18
DD263050A5 (de) 1988-12-21
SU1443796A3 (ru) 1988-12-07
NO165540B (no) 1990-11-19
US5068440A (en) 1991-11-26
FI865030A0 (fi) 1986-12-10
IE863102L (en) 1987-06-17
EP0230742A1 (en) 1987-08-05
DK585786D0 (da) 1986-12-05
NO2005022I1 (no) 2005-10-03
NL300065I1 (nl) 2001-12-01
JPH0144176B2 (OSRAM) 1989-09-26
IE59429B1 (en) 1994-02-23
CN86108547A (zh) 1987-08-19
GR3001069T3 (en) 1992-03-20
NO865093L (no) 1987-06-18
PT83958B (pt) 1989-05-12
ES2018163T4 (es) 2012-06-14
FI865030L (fi) 1987-06-18
ZA869078B (en) 1987-07-29
MX4684A (es) 1993-12-01
US4929629A (en) 1990-05-29
UA7206A1 (uk) 1995-06-30
EG17770A (en) 1991-03-30
IL80934A (en) 1990-07-26
YU205086A (en) 1987-12-31
FI90413C (fi) 1994-02-10
HUT45964A (en) 1988-09-28
KR870005961A (ko) 1987-07-08
JPS62155240A (ja) 1987-07-10
CN1016245B (zh) 1992-04-15
NO165540C (no) 1991-02-27
GB8531071D0 (en) 1986-01-29
ATE56942T1 (de) 1990-10-15

Similar Documents

Publication Publication Date Title
IN163129B (OSRAM)
IN164892B (OSRAM)
FR2637839B1 (OSRAM)
DE3690279T1 (OSRAM)
FR2578012B1 (OSRAM)
DE3690281T1 (OSRAM)
DE3590716T1 (OSRAM)
DE3590862T1 (OSRAM)
DE3690235T1 (OSRAM)
FR2579907B1 (OSRAM)
GR851775B (OSRAM)
IN165019B (OSRAM)
GR851807B (OSRAM)
GR851628B (OSRAM)
GR850768B (OSRAM)
GR850263B (OSRAM)
IN165028B (OSRAM)
GR852870B (OSRAM)
GR853092B (OSRAM)
IN163254B (OSRAM)
IN163318B (OSRAM)
IN163607B (OSRAM)
IN163714B (OSRAM)
BG45482A1 (OSRAM)
BG45260A1 (OSRAM)